Disparities in the prevalence and management of high-risk non-muscle invasive bladder cancer

被引:0
|
作者
Estevez, Angela [1 ]
Kaul, Sumedh [2 ]
Fleishman, Aaron [2 ]
Korets, Ruslan [1 ]
Chang, Peter [1 ]
Wagner, Andrew [1 ]
Bellmunt, Joaquim [3 ]
Olumi, Aria F. [1 ]
Rayala, Heidi [1 ]
Gershman, Boris [1 ]
机构
[1] Beth Israel Deaconess Med Ctr, Div Urol Surg, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA USA
[3] Dana Farber Canc Inst, Dept Med, Div Med Oncol, Boston, MA USA
关键词
Bladder cancer; Disparities; BCG; Non-muscle invasive; Carcinoma in situ; GUIDELINES;
D O I
10.1016/j.urolonc.2022.11.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To evaluate the associations of socioeconomic characteristics with the management of non-muscle invasive bladder cancer (NMIBC). Methods: We identified adult patients aged 18 to 89 years with Ta, T1, or Tis NMIBC in the NCDB. We then examined the associations of patient and socioeconomic characteristics with the guidelines-based management of high-risk NMIBC using multivariable logistic regression. Results: 163,949 patients were included in the study cohort, including 64% with Ta, 32% with T1, and 4% with Tis disease. Among those diagnosed with bladder cancer, male (OR 1.24, 95%CI 1.21-1.27), uninsured (OR 1.10, 95%CI 1.01-1.19 vs. private), and non-White (OR 1.34, 95%CI 1.28 -1.41 for Black; OR 1.10; 95%CI 1.03-1.18 for Other vs. White) patients were more likely to be diagnosed with high-risk disease, as well as patients from lower education level areas. Among those with high-risk NMIBC, patients who were older, non-White, Hispanic, uninsured or insured with Medic-aid were less likely to receive guideline recommended intravesical BCG, while those residing in rural and higher education level areas were more likely to receive BCG. When examining non-guidelines based use of radiotherapy for HGT1 disease, older age (OR 1.06; 95% CI 1.04-1.07) and VA/Military insurance (OR 2.73; 95%CI 1.07, 6.98 vs. private) were associated with radiotherapy use. Conclusion: There are strong disparities in the prevalence and management of high-risk NMIBC. These observations highlight impor-tant targets for future strategies to reduce such healthcare disparities and provide more equitable bladder cancer treatment to patients. ? 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:255e15 / 255e21
页数:7
相关论文
共 50 条
  • [41] Current Concepts in the Management of Non-Muscle Invasive Bladder Cancer
    Mandhani A.
    Indian Journal of Surgical Oncology, 2017, 8 (3) : 397 - 402
  • [42] MANAGEMENT OF VARIANT HISTOLOGY IN NON-MUSCLE INVASIVE BLADDER CANCER
    Prado, Kris
    Greenberg, Daniel
    Zhang, Chiyuan
    Sun, Andrew
    Skinner, Eila
    JOURNAL OF UROLOGY, 2020, 203 : E263 - E263
  • [43] CUA guidelines on the management of non-muscle invasive bladder cancer
    Kassouf, Wassim
    Traboulsi, Samer L.
    Kulkarni, Girish S.
    Breau, Rodney H.
    Zlotta, Alexandre
    Fairey, Andrew
    So, Alan
    Lacombe, Louis
    Rendon, Ricardo
    Aprikian, Armen G.
    Siemens, D. Robert
    Izawa, Jonathan I.
    Black, Peter
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2015, 9 (9-10): : E690 - E704
  • [45] SEQUENTIAL INTRAVESICAL GEMCITABINE AND DOCETAXEL FOR BCG-NAIVE HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER
    McElree, Ian M.
    Steinberg, Ryan L.
    Martin, Alexander C.
    Richards, Jordan
    Mott, Sarah L.
    Gellhaus, Paul T.
    Nepple, Kenneth G.
    O'Donnell, Michael A.
    Packiam, Vignesh T.
    JOURNAL OF UROLOGY, 2022, 207 (05): : E488 - E488
  • [46] Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer
    Fahmy, Mona
    Mansure, Jose Joao
    Brimo, Fadi
    Yafi, Faysal A.
    Segal, Robert
    Althunayan, Abdulaziz
    Hicks, Jessica
    Meeker, Alan
    Netto, George
    Kassouf, Wassim
    HUMAN PATHOLOGY, 2013, 44 (09) : 1766 - 1772
  • [47] Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer
    Audenet, Francois
    Farkas, Adam M.
    Anastos, Harry
    Galsky, Matthew D.
    Bhardwaj, Nina
    Sfakianos, John P.
    WORLD JOURNAL OF UROLOGY, 2018, 36 (11) : 1741 - 1748
  • [48] Treatment of high-risk, non-muscle-invasive bladder cancer
    Lerner, Seth P.
    NATURE CLINICAL PRACTICE UROLOGY, 2006, 3 (08): : 398 - 399
  • [49] Treatment of high-risk, non-muscle-invasive bladder cancer
    Seth P Lerner
    Nature Clinical Practice Urology, 2006, 3 : 398 - 399
  • [50] Immune phenotype of peripheral blood mononuclear cells in patients with high-risk non-muscle invasive bladder cancer
    François Audenet
    Adam M. Farkas
    Harry Anastos
    Matthew D. Galsky
    Nina Bhardwaj
    John P. Sfakianos
    World Journal of Urology, 2018, 36 : 1741 - 1748